Johnson & Johnson STEMI-DTU RCT: LV unloading with delayed reperfusion does not increase infarct size

Key highlights
  • Johnson & Johnson-sponsored STEMI-DTU RCT found Impella CP support >40 minutes before reperfusion did not change infarct size.
  • Trial protocol delayed PCI by 30 minutes.
  • Pre-PCI TIMI flow and coronary perfusion pressure improved after 30 minutes of Impella support.
  • Treatment arm had higher bleeding and vascular complications but no increase in 12-month mortality.

Trial overview

The STEMI-DTU randomized controlled trial tested whether left ventricular (LV) unloading with Impella CP followed by a 30-minute delay before percutaneous coronary intervention (PCI) reduces infarct size in anterior STEMI patients without cardiogenic shock.

Primary outcome

The primary endpoint was neutral: LV support plus delayed reperfusion did not reduce or increase myocardial infarct size versus immediate PCI; investigators note the hypertensive profile of enrolled patients may have limited LV unloading effect.

Key secondary findings

After 30 minutes of Impella support pre-PCI, TIMI flow and coronary perfusion pressure improved and protocol compliance was 100%; patients aged 61+ trended toward smaller infarcts (p=0.056); elevated lactate correlated with larger infarct size across the cohort.

Safety and implications

The treatment arm had higher bleeding and vascular complication rates but no increase in 12-month mortality; results support further mechanistic studies, including testing adjunct pharmacotherapies during the pre-PCI unloading window and targeted research in older or high-lactate subgroups.

Source: J&J

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

19 June 2026
Johnson & Johnson: MEMBRANE shows MMA embolization with TRUFILL n‑BCA reduces cSDH recurrence

Randomized MEMBRANE trial found adding middle meningeal artery embolization with TRUFILL n‑BCA to standard care lowered chronic subdural hematoma recurrence and re‑intervention.

18 December 2025
Johnson & Johnson's TRUFILL n-BCA Approved by FDA for Chronic Subdural Hematoma Treatment

FDA approves TRUFILL n-BCA for MMA embolization in chronic subdural hematoma, offering a minimally invasive alternative to surgery with proven safety and effectiveness.